Quince Therapeutics regains Nasdaq minimum bid price compliance; delisting risk removed

Quince Therapeutics, Inc.

On Nov 12, 2024, Nasdaq confirmed Quince regained compliance with $1.00 minimum bid price rule.
Compliance achieved after closing bid price stayed at or above $1.00 for 10 consecutive business days (Oct 29–Nov 11, 2024).
This resolves the non-compliance notice received June 20, 2024, and the matter is closed.
The company was facing potential delisting from Nasdaq Global Select Market if not compliant by Dec 17, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.